Weight Watchers Q2 2026 Earnings: Clinical Growth Could Not Offset Behavioral Decline

Weight Watchers (Nasdaq: WW) reported Q2 2026 revenue of $162.3 million, down 14.2% year over year, and diluted EPS of $1.41; a meaningful year-over-year EPS comparison is unavailable because of fresh start accounting following the company’s 2025 financial reorganization. Clinical growth and a favorable subscription mix lifted total ARPU, but the contraction in Behavioral subscribers continued to weigh on consolidated revenue.

Core Financial Results

Revenue declined as the 22.7% drop in Behavioral subscription revenue more than offset 30.4% growth in Clinical subscription revenue. Adjusted EBITDA reached $39.8 million, while GAAP net income included an $11.2 million income tax benefit and a $4.6 million gain on extinguishment of debt.

Weight Watchers emerged from its financial reorganization on June 24, 2025 and subsequently adopted fresh start accounting. The company provided a combined prior-year revenue figure because fresh start adjustments did not affect revenue, but most other GAAP measures are not directly comparable.

The adjusted gross margin was 73.6%, above the GAAP gross margin because the non-GAAP measure excludes specified items, including depreciation and amortization. The company said the adjusted margin remained near record levels.

Business and Segment Performance

The quarter showed a sharp divergence between Weight Watchers’ Behavioral and Clinical offerings. Clinical subscriber growth remained substantial, while the larger Behavioral subscriber base continued to contract. Core+, the company’s higher-value Behavioral tier, was an exception, recording its third consecutive quarter of sequential subscriber growth.

Clinical revenue grew more slowly than its subscriber count because Clinical ARPU declined. The company was also comparing against significant prior-year growth related to its former compounded semaglutide offering. Clinical subscribers were flat sequentially from Q1 after management reduced marketing investment following elevated peak-season spending.

Total subscription ARPU nevertheless increased because Clinical subscribers represented a larger share of the overall mix. That improvement helped moderate, but did not eliminate, the revenue effect of the lower total subscriber count.

Profitability, Cash Flow, and the Balance Sheet

Marketing expense was $47.9 million, or 29.5% of revenue, compared with $92.9 million in Q1 2026. Management attributed the sequential reduction to the end of peak season and a rebalancing of investment between business lines. The lower quarterly marketing burden supported positive operating cash flow, although it coincided with flat sequential Clinical subscribers.

Weight Watchers ended June with $101.5 million in cash and cash equivalents, down from $160.3 million at the end of 2025. For the first six months of 2026, operations used $9.3 million of cash, capitalized software and website development required $11.9 million, and long-term debt payments totaled $36.8 million. The positive $24.3 million of Q2 operating cash flow therefore marked an improvement from the first quarter’s cash consumption.

During Q2, the company used $36.8 million of cash to reduce term-loan principal by $41.4 million, including a voluntary prepayment completed at 68.5% of par. These actions reduced annualized interest expense by approximately $4 million. Long-term debt, net, declined to $424.0 million from $465.5 million at year-end, but the term loan still carried a 10.53% interest rate as of June 30.

2026 Guidance

Management reaffirmed its previously issued full-year guidance rather than raising or lowering the ranges. The unchanged outlook indicates that the company continues to base its plan on further progress in Clinical and Core+ while managing the broader Behavioral decline and marketing spending.

Risks Investors Need to Watch

• Behavioral contraction remains the main revenue pressure. Behavioral subscription revenue fell 22.7%, and end-of-period Behavioral subscribers declined 24.6%. Because Behavioral remains the larger business, continued contraction could offset further Clinical growth.
• Clinical subscriber growth is not translating proportionally into revenue. Clinical subscribers increased 55.7%, but Clinical revenue rose 30.4% as Clinical ARPU declined 13.4%. The economics of future Clinical growth will therefore be as important as subscriber additions.
• Marketing efficiency involves a growth trade-off. Marketing expense fell sharply from Q1, supporting cash generation, but Clinical subscribers were flat sequentially after the company recalibrated spending.
• Debt remains costly despite the Q2 reduction. The company lowered principal and future interest expense, but net long-term debt remained $424.0 million and the term loan rate was 10.53% at quarter-end.
• Fresh start accounting limits historical comparisons. Revenue can be compared using the company’s combined prior-year presentation, but many GAAP profit and EPS comparisons are distorted by the 2025 reorganization and accounting reset.

Summary

Weight Watchers’ Q2 2026 results showed progress in Clinical, Core+, ARPU, and quarterly cash generation, but those gains did not offset the continued decline in the broader Behavioral subscriber base. The company also reduced debt and reaffirmed its full-year outlook. The main issues to monitor are whether Clinical and Core+ can sustain growth with lower marketing investment, whether Clinical ARPU stabilizes, and whether positive operating cash flow continues while the company services its remaining debt.